CN1105236A - Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof - Google Patents
Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof Download PDFInfo
- Publication number
- CN1105236A CN1105236A CN 93114694 CN93114694A CN1105236A CN 1105236 A CN1105236 A CN 1105236A CN 93114694 CN93114694 CN 93114694 CN 93114694 A CN93114694 A CN 93114694A CN 1105236 A CN1105236 A CN 1105236A
- Authority
- CN
- China
- Prior art keywords
- aerosol
- sodium
- preventing transmission
- treatment
- propellant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The aerosol for preventing the transmission of and curing lung tuberculosis features its atomizing application to create a new way of administration.
Description
The invention belongs to a kind of pharmaceutical preparation and preparation method.
Public media and clinical report repeatedly once in recent years, pulmonary tuberculosis is trend occurred frequently in recent years in worldwide, submit to the public to improve control lungy consciousness whereby.At present the anti-tuberculosis drugs of using clinically mainly is by oral or inject two administrations.Because the restriction of the property of medicine, antibacterial characteristic and route of administration occurs then involving relevant internal organs when dosage is big often, and toxigenicity; Dosage hour then brings out antibacterial and produces Resistant strain and drug resistance occurs, thereby give clinical treatment lungy, bring very burden, forward attention to atomizing suction topical for addressing the above problem the existing medical worker of part, in the hope of improving the drug level of lesions position, reduce the medication total amount, reduce toxicity.As " clinical medicine " 1989,9(5)-two attached institutes of 205-206 Xinxiang College of Medical Science, ultrasonic atomizatios such as Liu Duowu suction antituberculosis drugs is treated long-term discharge of bacteria pulmonary tuberculosis 38 examples and is gain the curative effect of making us inspiring very much happily; " Chinese Hospitals pharmaceutical journal " 1983,3(2)-5-7, the rifampicin powder aerosol clinical practice curative effect of developments such as Shanghai City Luwan District central hospital soup state post also belongs to superior; " pharmacy circular " 1980,15(8)-15 Qiao Zhang of Pharmacy department of Suzhou City's infectious disease tuberculosis hospital star trial-production and the streptomycin powder aerosol used, its clinical practice also obtains gratifying result, but as if the angle from pharmaceutics and industrialized great production, above-mentioned three examples all have deficiency separately.Ultrasonic atomizatio inhalation apparatus cost is too high, so can only carry out in hospital, can not enter huge numbers of families, is unsuitable for extensive patients and carries use; The rifampicin powder aerosol, because isceon and dichlorodifluoromethane in the prescription all have certain dissolubility to the crude drug rifampicin, simultaneously again owing to do not add in the prescription of this aerosol and do not make a gesture of measuring regulator, so this aerosol is placed and is produced recrystallization after a period of time and make partially crystallizable become big and the granule come-up is inter-adhesive and to block shower nozzle be inevitable thing; There is not adding to be difficult to be adapted to industrialized great production in the prescription of streptomycin powder aerosol for the ease of the dosage control that packing increases volumetrical latent solvent matchmaker isceon so that packing operation, simultaneously owing to do not add the proportion regulator in the prescription yet, therefore be directed at aerosol too and placed granule come-up after a period of time, inter-adhesive and phenomenon that block shower nozzle takes place.Medicine also is difficult to enter pulmonary under this granularity simultaneously.
But the objective of the invention is provides the pulmonary tuberculosis preventing transmission of the direct administration of focus and treatment with aerosol and preparation method thereof some antitubercular agent being modified on the salifiable basis to society.
Pulmonary tuberculosis preventing transmission of the present invention and treatment can be divided into two kinds of solution-type and suspension types with aerosol, now state as follows:
Solution-type pulmonary tuberculosis preventing transmission and treatment are by medicine with aerosol; Formations such as latent solvent matchmaker, propellant, its Chinese medicine is optional; Should account for the 1-22% of aerosol total amount with wherein at least a its consumptions such as ebutol, Tuborin, rifampicin sodium, rifandin sodium, R-77-3 sodium; The optional water of latent solvent matchmaker, ethanol, propylene glycol, dimethyl sulfoxide etc. are wherein at least a, and its consumption should account for the 10-90% of aerosol total amount; Propellant can be selected compressed air for use, nitrous oxide, nitrogen, carbon dioxide, and liquid gas, Hydrocarbon, fluorine alkyl chloride chemical compounds etc. are wherein at least a, and its consumption should account for the 10-30% of aerosol total amount.Its preparation method is by feeding intake, adjusts, and check, packing, charges into several procedures such as propellant and finishes at gland.
Suspension type pulmonary tuberculosis preventing transmission and treatment are to be made of with latent solvent matchmaker, propellant etc. medicine, proportion regulator, suspending agent, increase volume with aerosol, the optional 2-22% that should account for the aerosol total amount with wherein at least a its consumptions such as sodium isonicotinylhydrazide methanesulfonate, hydrochloric acid isoniazid, hydrochloric acid pyrazinamide, ebutol, rifampicin sodium, rifamdin sodium, R-77-3 sodium streptomycin, sodium aminosalicylate of its Chinese medicine; The 0-20% suspending agent that the proportion regulator can select for use anhydrous sodium sulfate or its consumption of Lactis Anhydrous should account for the aerosol total amount can be selected Arlacel-85 or ethyl oleate for use, and its consumption should account for the 1-20% of aerosol total amount; The latent solvent matchmaker can select isceon or vegetable oil for use, and its consumption should account for the 10-50% of aerosol total amount; Propellant can be selected dichlorodifluoromethane or dichlorotetra-fluoroethane for use, and its consumption should account for the 40-80% of aerosol total amount.Its preparation method is by pulverizing, feed intake, adjustment, packing, gland, charging into several procedures such as propellant and finish.
Aerosol is used in pulmonary tuberculosis preventing transmission that the present invention produces and treatment, is another route of administration of antitubercular agent.But this preparation is compared the direct administration of its indication pulmonary tuberculosis focus, or injection oral with traditional route of administration of antitubercular agent, and it is little to have an overall dosage, local lesion's drug level height, the curative effect height, instant effect, toxic and side effects is little, but the painless characteristics of waiting bitterly for of patient's self-administration.Again because aerosol is the pulmonary administration by respiratory tract, medicine that respiratory tract is remaining and respiratory tract progressively on the sputum that moves time enough is arranged, the space fully contacts, tubercule bacillus number in the sputum of patient's expectoration is reduced rapidly or disappear, thereby to controlling phthisical propagation and phthisical control has certain positive effect.
For the present invention is further illustrated, provide the preparation method of following embodiment 1, solution-type Tuborin aerosol: prescription: Tuborin 75g, propylene glycol 25g, ethanol 460g, dichlorodifluoromethane 350g.Method for making: in the ethanol that is equivalent to 3/4 amount that Tuborin is dissolved in, add propylene glycol then, to capacity, filter, after the assay was approved, be sub-packed in 100 bottles, gland, charge into the 3.5g dichlorodifluoromethane promptly by every bottle on valve on the lid with ethanol dilution.
The preparation method of embodiment 2, suspension type sodium isonicotinylhydrazide methanesulfonate aerosol, learn from else's experience sodium isonicotinylhydrazide methanesulfonate 50g, anhydrous sodium sulfate 45g below 5 μ m of the particle diameter pulverized by jet mill, with the 42g Arlacel-85 with placing newborn body to grind evenly, add the 400g Dichloromonofluoromethane and grind to form homogenate, and move in the adjustment cylinder, stir, after the assay was approved, be sub-packed in 100 aluminum Room bottles, gland also charges into the 9g dichlorodifluoromethane promptly by every bottle on valve on the lid.
Claims (9)
1, a kind of solution-type pulmonary tuberculosis preventing transmission and treatment aerosol, it is characterized in that this aerosol is to be made of medicine, latent solvent matchmaker, propellant etc., its Chinese medicine is optional wherein at least a with ebutol, Tuborin, rifampicin sodium, rifandin sodium, R-77-3 sodium etc.; The optional water of latent solvent matchmaker, ethanol, propylene glycol, dimethyl sulfoxide etc. are wherein at least a; Propellant can select for use compressed air carbon dioxide, nitrous oxide, nitrogen, liquid gas, Hydrocarbon, fluorine alkyl chloride chemical compound etc. wherein at least a.
2, pulmonary tuberculosis preventing transmission as claimed in claim 1 and treatment aerosol, the percentage ratio that it is characterized in that constituting each ingredients constitute aerosol content total amount of aerosol content is medicine 1-22%, latent solvent matchmaker 10-90% propellant 10-80%.
3, aerosol is used in a kind of solution-type pulmonary tuberculosis preventing transmission and treatment, it is characterized in that this aerosol is by feeding intake, adjust, check, packing, gland, charging into several procedures such as propellant and finish.
4, a kind of suspension type pulmonary tuberculosis preventing transmission and treatment aerosol, the content that it is characterized in that this aerosol is to be made of medicine, proportion regulator, suspending agent, latent solvent matchmaker, propellant etc., its Chinese medicine is optional with sodium isonicotinylhydrazide methanesulfonate, hydrochloric acid isoniazid, hydrochloric acid pyrazinamide, ebutol, rifampicin sodium, rifamdin sodium, R-77-3 sodium, streptomycin, and sodium aminosalicylate etc. are wherein at least a; The proportion regulator can be selected anhydrous sodium sulfate or Lactis Anhydrous for use; Suspending agent can be selected Arlacel-85 for use, or ethyl oleate; The latent solvent matchmaker can select isceon or vegetable oil for use; Propellant can be selected dichlorodifluoromethane or dichlorotetra-fluoroethane for use.
5, aerosol is used in suspension type pulmonary tuberculosis preventing transmission as claimed in claim 4 and treatment, and the percentage ratio that it is characterized in that constituting each ingredients constitute aerosol content total amount of this aerosol content is total thing 2-22%; Proportion regulator 0-20%; Suspending agent 1-20%; Latent solvent matchmaker 10-50%; Propellant 40-80%.
6, aerosol use in a kind of suspension type pulmonary tuberculosis preventing transmission and treatment, it is characterized in that this aerosol is by pulverizing, feeds intake, adjustment, packing, gland, charges into several procedures such as propellant and finish.
7, suspension type pulmonary tuberculosis preventing transmission as claimed in claim 6 and treatment be with the preparation method of aerosol, and no matter the solid drugs and the proportion regulator of the usefulness that it is characterized in that feeding intake via which kind of grinding mode are pulverized, and its granularity must reach below the 10 μ m.
8, suspension type pulmonary tuberculosis preventing transmission as claimed in claim 6 and treatment be with the preparation method of aerosol, it is characterized in that adjusting, packing, gland, etc. the temperature of three process operating system must be controlled at below 23 ℃.
9, suspension type pulmonary tuberculosis preventing transmission as claimed in claim 6 and treatment aerosol, it is characterized in that pulverizing, the measure that feed intake, several procedures such as adjustment, packing, gland and all raw material, adjuvants all should be taked strict control moisture, the finished product water content should be controlled at below the 300ppm.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93114694 CN1105236A (en) | 1993-11-13 | 1993-11-13 | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof |
| CN 94104237 CN1134278A (en) | 1993-11-13 | 1994-04-24 | Aerosol for preventing and curing pulmonary tuberculosis and its preparing method and synergy method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93114694 CN1105236A (en) | 1993-11-13 | 1993-11-13 | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1105236A true CN1105236A (en) | 1995-07-19 |
Family
ID=4990607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93114694 Pending CN1105236A (en) | 1993-11-13 | 1993-11-13 | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1105236A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102413837A (en) * | 2009-04-24 | 2012-04-11 | 国立血清研究所 | A tuberculosis tb vaccine to prevent reactivation |
| CN105025921A (en) * | 2013-03-15 | 2015-11-04 | 宾夕法尼亚大学理事会 | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
-
1993
- 1993-11-13 CN CN 93114694 patent/CN1105236A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102413837A (en) * | 2009-04-24 | 2012-04-11 | 国立血清研究所 | A tuberculosis tb vaccine to prevent reactivation |
| CN102413837B (en) * | 2009-04-24 | 2015-11-25 | 国立血清研究所 | The tuberculosis TB vaccine of prevention reactivation |
| CN105025921A (en) * | 2013-03-15 | 2015-11-04 | 宾夕法尼亚大学理事会 | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
| CN105025921B (en) * | 2013-03-15 | 2019-02-19 | 宾夕法尼亚大学理事会 | Synthetic immunogen for prevention lungy or treatment |
| US10953079B2 (en) | 2013-03-15 | 2021-03-23 | The Trustees Of The University Of Pennsylvania | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103393607A (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| HUP0102892A2 (en) | Drug delivery system comprising a tightly compacted solid medicament stock, process for its preparation and for its use | |
| CN107073016A (en) | Celastrol and derivative for treating obesity | |
| JPH03167119A (en) | Pharmaceuticals | |
| CN110054624A (en) | Berberine hydrochloride and caffeic acid eutectic object and preparation method and its composition and purposes | |
| CN104822374A (en) | Compounds for treatment of obesity and methods of use thereof | |
| CN106667975A (en) | Preparation method of ipratropium bromide solution for inhalation | |
| EP2651414A1 (en) | Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer | |
| CN1154495C (en) | Use of mirtazapine for treating sleep apneas | |
| Sivak et al. | Management of hypoventilation in motor neuron disease presenting with respiratory insufficiency | |
| WO2022116792A1 (en) | Isoniazid dry powder inhalant for treating pulmonary tuberculosis | |
| CN109793740A (en) | Application of the pazopanib hydrochloride in preparation treatment pulmonary fibrosis disease drug | |
| KR20150011379A (en) | Methods and compositions for administration of oxybutynin | |
| US20140163044A1 (en) | Compound Chemical Medicine Acting on Respiratory Disease, Preparation Process and Use Thereof | |
| CN1105236A (en) | Aerosol for preventing transmission and curing of lung tuberculosis and preparing process thereof | |
| CN108938650A (en) | The application of cinobufagin | |
| CN101982174A (en) | Formula of compound medicine preparation for relieving cough and preventing asthma and preparation method thereof | |
| CN111840512B (en) | Composition for treating cartilage repair and/or osteoarthritis | |
| US11793852B2 (en) | Application of Longhu Rendan in preparing medicament for preventing and/or treating liver fibrosis | |
| JPS624229A (en) | Analgesic and antiinflammatory medicine | |
| CN102626411A (en) | Pharmaceutical composition containing propofol and opioid analgesics and use thereof | |
| CN1289085C (en) | Nasal spray agent | |
| CN100493501C (en) | Scopolamine hydrobromide dry powder inhalant for nose and preparing method | |
| Storms | Patient compliance with bronchodilator therapy in asthma | |
| CN113332314B (en) | Oyster shell meat zymolyte and application thereof in preparation of medicines for treating depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication |